Canadian Cancer Trials Group Bulletins

General


Survival Benefit from Brain Cancer Regimen Persists

Updated results of EORTC 26981/Canadian Cancer Trials Group CE.3 show that patients with brain cancer who received a combination of temozolomide (Temodar) and radiotherapy lived longer than those who received radiotherapy alone, and evidence of a benefit was seen in some patients for up to 5 years.

These results are published online March 9 in The Lancet Oncology and are highlighted in the current NCI Bulletin.

The Lancet Oncology ONLINE:
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups and the National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (ONLINE).
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70025-7/fulltext

NCI Bulletin:
http://www.cancer.gov/ncicancerbulletin/031009/page3